Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
June 07, 2023 05:35 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the hiring of Owen Watson, MS. Mr. Watson’s...
NordLayer launches a new and one-of-the-kind Browser Extension
May 24, 2023 10:16 ET
|
NordLayer
LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- The NordLayer team is happy to announce that from now on, people can access their business resources via a browser extension. The extension introduces a new...
Global Microcontroller Market Anticipated to Garner $56.3 Billion, Growing at a 11.7% CAGR in the 2022–2031 Timeframe [260-Pages] | Backed by Research Dive
May 22, 2023 09:01 ET
|
Research Dive
New York, USA, May 22, 2023 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global microcontroller market. According to the report, the global market is projected to surpass...
The Automated Guided Vehicles Market is projected to grow from USD 2.17 billion in 2022 to USD 4.11 billion by 2030, exhibiting a CAGR of 9.6% during the forecast period.| Data By Contrive Datum Insights Pvt Ltd.
May 11, 2023 17:00 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, May 11, 2023 (GLOBE NEWSWIRE) -- The Global Automated Guided Vehicles Market is projected to grow from USD 2.17 billion in 2022 to USD 4.11 billion by 2030, exhibiting a CAGR of 9.6%...
Ambarella Announces First Quarter Fiscal Year 2024 Earnings Conference Call to be Held May 30, 2023
May 09, 2023 05:00 ET
|
Ambarella
SANTA CLARA, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced it will hold its first quarter fiscal year 2024 earnings...
Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa
May 04, 2023 03:00 ET
|
Endogena
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed...
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
April 12, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 11, 2023 07:00 ET
|
ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
Vision Correction Market to reach USD 42.7 Mn by 2029 at a CAGR of 8.9 percent – says Maximize Market Research
April 10, 2023 07:36 ET
|
MAXIMIZE MARKET RESEARCH PRIVATE LIMITED
Pune, April 10, 2023 (GLOBE NEWSWIRE) -- A global Healthcare business consulting and research firm, Maximize Market Research, has published a market intelligence and competitive landscape report on...
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
March 08, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...